- $1.01bn
- $608.91m
- 25
- 15
- 60
- 24
Annual income statement for 89bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 49.4 | 89.7 | 102 | 152 | 386 |
| Operating Profit | -49.4 | -89.7 | -102 | -152 | -386 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -49.6 | -90.3 | -102 | -138 | -366 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -49.5 | -90.1 | -102 | -142 | -367 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -49.5 | -90.1 | -102 | -142 | -367 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -49.5 | -90.1 | -102 | -142 | -367 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.08 | -4.48 | -2.93 | -1.99 | -3.5 |